Citations

Clear

4847 citation(s) found for "Tu, Eric".

Regional metabolic patterns in mild cognitive impairment and Alzheimer’s disease
Kantarci, Kejal , Jack, Clifford R. , Xu, Yun , Campeau, Norberg G., O’Brien, Peter C. , Ivnik, Robert J., Kokmen, E., Tangalos, Eric G., Petersen, R. C., Smith, Glenn E. , Boeve, Bradley F. , Jack, Clifford R , Kantarci, Kejal

Mayo Clinic

Neurology | May 13, 2012 | Volume: 55 | Issue: 2 | Pages: 210-217

10.1212/wnl.55.2.210 | PMID 10908893 Get It

Rate of medial temporal lobe atrophy in typical aging and Alzheimer's disease
Jack, Clifford R. , Petersen, Ronald , Xu, YC , O’Brien, Peter C. , Ivnik, Robert J., Tangalos, Eric G., Kokmen, E., Smith, Glenn E. , Jack, Clifford R

Mayo Clinic

Neurology | May 13, 2012 | Volume: 51 | Issue: 4 | Pages: 993-999

10.1212/wnl.51.4.993 | PMID 9781519 Get It

Medial temporal atrophy on MRI in normal aging and very mild Alzheimer's disease
Jack, Clifford R. , Petersen, Ronald C. , Waring, Stephen C. , O’Brien, Peter C. , Tangalos, Eric G., Ivnik, Robert J., Kokmen, Emre, Xu, Yue Cheng , Smith, Glenn E. , Waring, Stephen C. , Jack, Clifford R

Mayo Clinic

Neurology | May 13, 2012 | Volume: 49 | Issue: 3 | Pages: 786-794

10.1212/wnl.49.3.786 | PMID 9305341 Get It

MR‐based hippocampal volumetry in the diagnosis of Alzheimer's disease
Jack, Clifford R. , Petersen, Ronald C. , O’Brien, Peter C. , Tangalos, Eric G., Jack, Clifford R

Mayo Clinic

Neurology | May 13, 2012 | Volume: 42 | Issue: 1 | Pages: 183-183

10.1212/wnl.42.1.183 | PMID 1734300 Get It

Genomic Association Analysis Identifies Multiple Loci Influencing Antihypertensive Response to an Angiotensin II Receptor Blocker
Bailey, Kent R. , Schwartz, Gary L. , Chapman, Arlene B. , Chai, High Seng, Boerwinkle, Eric , Turner, Stephen T.

Mayo Clinic

Hypertension | May 8, 2012 | Volume: 59 | Issue: 6 | Pages: 1204-1211

10.1161/hyp.0b013e31825b30f8 | PMID 22566498 Get It

To identify genes influencing blood pressure response to an angiotensin II receptor blocker, single nucleotide polymorphisms identified by genome-wide association analysis of the response to candesartan were validated by opposite direction associations with the response to a thiazide diuretic, hydrochlorothiazide. We sampled 198 white and 193 blacks with primary hypertension from opposite tertiles of the race-sex–specific distributions of age-adjusted diastolic blood pressure response to candesartan. There were 285 polymorphisms associated with the response to candesartan at P <10 −4 in whites. A total of 273 of the 285 polymorphisms, which were available for analysis in a separate sample of 196 whites, validated for opposite direction associations with the response to hydrochlorothiazide (Fisher χ 2 1-sided P =0.02). Among the 273 polymorphisms, those in the chromosome 11q21 region were the most significantly associated with response to candesartan in whites (eg, rs11020821 near FUT4 , P =8.98×10 −7 ), had the strongest opposite direction associations with response to hydrochlorothiazide (eg, rs3758785 in GPR83 , P =7.10×10 −3 ), and had the same direction associations with response to candesartan in the 193 blacks (eg, rs16924603 near FUT4 , P =1.52×10 −2 ). Also notable among the 273 polymorphisms was rs11649420 on chromosome 16 in the amiloride-sensitive sodium channel subunit SCNN1G involved in mediating renal sodium reabsorption and maintaining blood pressure when the renin-angiotensin system is inhibited by candesartan. These results support the use of genomewide association analyses to identify novel genes predictive of opposite direction associations with blood pressure responses to inhibitors of the renin-angiotensin and renal sodium transport systems.
Added Value of a Serum Proteomic Signature in the Diagnostic Evaluation of Lung Nodules
Pecot, Chad V. , Li, Ming , Zhang, Xueqiong J., Rajanbabu, Rama, Calitri, Ciara, Bungum, Aaron O., Jett, James R., Putnam, Joe B. , Callaway‐Lane, Carol , Deppen, Steve, Grogan, Eric L. , Worrell, John A., Shyr, Yu , Massion, Pierre P. , Carbone, David Paul , Moons, Karel G.M.

Mayo Clinic

Cancer Epidemiology, Biomarkers & Prevention | May 7, 2012 | Volume: 21 | Issue: 5 | Pages: 786-792

10.1158/1055-9965.epi-11-0932 | PMID 22374995 Get It

Abstract Background: Current management of lung nodules is complicated by nontherapeutic resections and missed chances for cure. We hypothesized that a serum proteomic signature may add diagnostic information beyond that provided by combined clinical and radiographic data. Methods: Cohort A included 265 and cohort B 114 patients. Using multivariable logistic regression analysis we calculated the area under the receiver operating characteristic curve (AUC) and quantified the added value of a previously described serum proteomic signature beyond clinical and radiographic risk factors for predicting lung cancer using the integration discrimination improvement (IDI) index. Results: The average computed tomography (CT) measured nodule size in cohorts A and B was 37.83 versus 23.15 mm among patients with lung cancer and 15.82 versus 17.18 mm among those without, respectively. In cohort A, the AUC increased from 0.68 to 0.86 after adding chest CT imaging variables to the clinical results, but the proteomic signature did not provide meaningful added value. In contrast, in cohort B, the AUC improved from 0.46 with clinical data alone to 0.61 when combined with chest CT imaging data and to 0.69 after adding the proteomic signature (IDI of 20% P = 0.0003). In addition, in a subgroup of 100 nodules between 5 and 20 mm in diameter, the proteomic signature added value with an IDI of 15% (P ≤ 0.0001). Conclusions: The results show that this serum proteomic biomarker signature may add value to the clinical and chest CT evaluation of indeterminate lung nodules. Impact: This study suggests a possible role of a blood biomarker in the evaluation of indeterminate lung nodules. Cancer Epidemiol Biomarkers Prev; 21(5); 786–92. ©2012 AACR.
Influence of Mitral Regurgitation Repair on Survival in the Surgical Treatment for Ischemic Heart Failure Trial
Grayburn, Paul , Sun, Benjamin , Rao, Vivek , She, Lilin , Jain, Anil, Chua, Yeow Leng , Daly, Richard C. , Senni, Michele , Mokrzycki, Krzysztof , Menicanti, Lorenzo , Oh, Jae K. , Michler, Robert E. , Wróbel, Krzysztof , Lee, Kerry L. , Deja, Marek Andrzej , Krejca, Michał , Lamy, Andre L. , Velazquez, Eric J. , Jones, Robert H. , Senni, Michele

Mayo Clinic

Circulation | May 2, 2012 | Volume: 125 | Issue: 21 | Pages: 2639-2648

10.1161/circulationaha.111.072256 | PMID 22553307 Get It

Background— Whether mitral valve repair during coronary artery bypass grafting (CABG) improves survival in patients with ischemic mitral regurgitation (MR) remains unknown. Methods and Results— Patients with ejection fraction ≤35% and coronary artery disease amenable to CABG were randomized at 99 sites worldwide to medical therapy with or without CABG. The decision to treat the mitral valve during CABG was left to the surgeon. The primary end point was mortality. Of 1212 randomized patients, 435 (36%) had none/trace MR, 554 (46%) had mild MR, 181 (15%) had moderate MR, and 39 (3%) had severe MR. In the medical arm, 70 deaths (32%) occurred in patients with none/trace MR, 114 (44%) in those with mild MR, and 58 (50%) in those with moderate to severe MR. In patients with moderate to severe MR, there were 29 deaths (53%) among 55 patients randomized to CABG who did not receive mitral surgery (hazard ratio versus medical therapy, 1.20; 95% confidence interval, 0.77–1.87) and 21 deaths (43%) among 49 patients who received mitral surgery (hazard ratio versus medical therapy, 0.62; 95% confidence interval, 0.35–1.08). After adjustment for baseline prognostic variables, the hazard ratio for CABG with mitral surgery versus CABG alone was 0.41 (95% confidence interval, 0.22–0.77; P =0.006). Conclusion— Although these observational data suggest that adding mitral valve repair to CABG in patients with left ventricular dysfunction and moderate to severe MR may improve survival compared with CABG alone or medical therapy alone, a prospective randomized trial is necessary to confirm the validity of these observations. Clinical Trial Registration— URL: http://www.clinicaltrials.gov . Unique identifier: NCT00023595.
Evidence-based guideline update: NSAIDs and other complementary treatments for episodic migraine prevention in adults: [RETIRED]
Holland, Starr, Silberstein, Stephen D., Freitag, F. G., Argoff, Charles E. , Ashman, Eric, Ibáñez, Agustín , Dodick, David W. , Ibañez, Agustín

Mayo Clinic

Neurology | April 23, 2012 | Volume: 78 | Issue: 17 | Pages: 1346-1353

10.1212/wnl.0b013e3182535d0c | PMID 22529203 Get It

Evidence-based guideline update: Pharmacologic treatment for episodic migraine prevention in adults
Holland, Starr, Freitag, F. G., Argoff, Charles E. , Ashman, Eric, Silberstein, Stephen D. , Dodick, David W.

Mayo Clinic

Neurology | April 23, 2012 | Volume: 78 | Issue: 17 | Pages: 1337-1345

10.1212/wnl.0b013e3182535d20 | PMID 22529202 Get It